果中的多糖具有不同的特性,通过恢复肠道屏障功能和微生物群平衡来改善DSS诱导的性结肠炎
Jieqiong Yao1,2,3, Siyi Pan1,2,3
1College of Food Science and Technology, Huazhong Agricultural University, Wuhan 430070, China.
Foods (Basel, Switzerland)
|January 10, 2026
概括
来自具有优越特征的水果的类多糖体显示出最大的潜力来缓解性结肠炎 (UC) 症状. 这些化合物调节肠道微生物群并减少炎症,为炎症性肠病的饮食干预提供了基础.
科学领域:
- 食品科学 食品科学 食品科学
- 免疫学 免疫学 免疫学
- 微生物组研究 微生物组研究
背景情况:
- 类水果的质地,通过的特征表明,影响多糖的生物活性.
- 性结肠炎 (UC) 是一种具有有限治疗选择的炎症性肠病.
研究的目的:
- 在实验性性结肠炎中,比较果肉多糖的保护作用,具有不同的口特征.
- 研究这些多糖类对肠道微生物群组成和短链脂肪酸生产的影响.
主要方法:
- 在小鼠中诱导了性结肠炎.
- 来自Hongmeiren (HMR,高级),Satsuma (WM,中等级) 和南普通 (NF,较低级) 类水果的果粉多糖被管理.
- 分析了UC症状,炎症标记物 (TNF-α,IL-6,IL-10),肠道屏障蛋白 (ZO-1,Occludin,MUC2),肠道微生物群和短链脂肪酸.
主要成果:
- 所有类多糖都减轻了UC症状.
- 洪梅林 (HMR) 多糖体表现出最显著的抗炎作用,减少TNF-α,增加IL-10,ZO-1,奥克卢丁和MUC2的表达.
- 类多糖因抑制有害细菌 (Escherichia-Shigella,Helicobacter) 和丰富有益的属 (Akkermansia,norank_f_Muribaculaceae) 而调节肠道微生物群.
- 特定的类型选择性地改变了微生物群落,并促进了短链脂肪酸生产,特别是酸盐和丁酸盐.
结论:
- 类水果的特性与它们在缓解大肠炎方面的有效性密切相关.
- 优越的特性类多糖提供强大的抗炎和肠道保护作用.
- 这些发现支持使用特定的类品种用于功能性食物的开发和对炎症性肠道疾病的饮食干预.
相关概念视频
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
1.4K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.4K
Drugs for Treatment of Diarrhea-Predominant IBS
615
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
615
Drugs for Treatment of Ulcerative Colitis in IBD
448
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
448
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
1.1K
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
1.1K
Drugs for Treatment of Constipation-Predominant IBS
688
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
688
Mucosal Barrier of the Stomach
2.0K
The gastric glands contain parietal cells that secrete hydrochloric acid (HCl) for digestion. The cells secrete HCl because it is highly corrosive and essential for breaking down food. To achieve this, they secrete hydrogen and chloride ions into the lumen of the gastric glands, which combine to form HCl.
Within parietal cells, carbonic acid is first formed through the reaction of water and carbon dioxide. The dissociation of carbonic acid releases bicarbonate and hydrogen ions. The bicarbonate...
Within parietal cells, carbonic acid is first formed through the reaction of water and carbon dioxide. The dissociation of carbonic acid releases bicarbonate and hydrogen ions. The bicarbonate...
2.0K


